Courtney Miller

Courtney Miller is a Professor and Director of Academic Affairs at the University of Florida, conducting research at the Scripps Research campus in Jupiter, Florida. Her work integrates neuroscience, drug discovery, and cancer therapeutics to target memory mechanisms in neuropsychiatric disorders and malignancies.

Her educational foundation includes:

• Ph.D. in Neurobiology from University of California, Irvine (2005)
• Bachelor's of Science in Biopsychology from University of California, Santa Barbara (1999)
• Technology Ventures Certification from Collat School of Business (2007-2009)

Research centers on memory neurobiology in substance use disorders and PTSD, with emphasis on molecular nanomotors like non-muscle myosin II. Her lab uniquely bridges in vivo circuit analysis with drug development, targeting therapeutic applications for glioblastoma, pancreatic cancer, and addiction through dual-branched methodology.

Publication trends reveal progression from foundational epigenetic memory mechanisms (2010-2011) to contemporary myosin-targeted therapeutics (2025). Key interdisciplinary threads include: synaptic actin-myosin dynamics in memory consolidation, polydrug association modeling, and translating basic discoveries into clinically viable inhibitors for cancer metastasis and neuropsychiatric conditions.

Major recognitions include:

• Presidential Early Career Award for Scientists and Engineers (2016)
• Election to American College of Neuropsychopharmacology (2020)
• NIDA Young Investigator Award (2005)
• Multiple Faculty of 1000 Selections (2007-2013)

As Principal Investigator on 16+ active NIH/NSF grants totaling $15M+, she leads projects spanning myosin inhibitor development for glioblastoma (NINDS), stress-vulnerability in addiction (NIDA), and REU training programs. Entrepreneurial ventures include co-founding Myosin Therapeutics (2020) and Professional Women's Nexus (2007), reflecting her commitment to translational science and mentorship.

The Miller Lab maintains dual operational branches: one investigating memory-circuit-molecular interactions in addiction/PTSD using advanced microscopy, and another developing high-throughput screening platforms for myosin-targeted therapeutics. Collaborations with Mayo Clinic and Verisim Life accelerate preclinical translation, while her NSF REU site trains next-generation interdisciplinary scientists.